Schrödinger

124 articles about Schrödinger

• Schrödinger to Present at Goldman Sachs 44th Annual Global Healthcare Conference

  6/1/2023

  Schrödinger today announced that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference.

• Schrödinger to Present at Jefferies Global Biopharma Conference

  5/26/2023

  Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 25, 2023

  5/25/2023

  Schrödinger, Inc. reported that on May 19, 2023, the company granted non-statutory stock options to purchase 7,660 shares of the company’s common stock to five newly hired employees and restricted stock units with respect to 1,988 shares of the company’s common stock to two newly hired employees.

• Schrödinger Reports Strong First Quarter 2023 Financial Results

  5/4/2023

  Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the first quarter ended March 31, 2023.

• Schrödinger Publishes Inaugural Corporate Sustainability Report

  4/27/2023

  Schrödinger, Inc. today published its inaugural Corporate Sustainability Report.

• Schrödinger to Announce First Quarter 2023 Financial Results on May 4

  4/20/2023

  Schrödinger will report its first quarter 2023 financial results on Thursday, May 4, 2023, after the financial markets close.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 19, 2023

  4/19/2023

  Schrödinger, Inc. today reported that on April 14, 2023, the company granted (i) a non-statutory stock option to purchase 2,400 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSU) with respect to 1,800 shares of the company’s common stock to one newly hired employee.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 22, 2023

  3/22/2023

  Schrödinger, Inc. today reported that on March 19, 2023, the company granted non-statutory stock options to purchase an aggregate of 32,700 shares of the company’s common stock to 10 newly hired employees, including two newly hired employees based outside of the United States.

• Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results

  2/28/2023

  Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided its financial outlook for 2023.

• Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 17, 2023

  2/17/2023

  Schrödinger, Inc. reported that on February 15, 2023, the company granted non-statutory stock options to purchase an aggregate of 45,600 shares of the company’s common stock to 11 newly hired employees, including two newly hired employees based outside of the United States.

• Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda

  2/14/2023

  Schrödinger Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported the receipt of an $111.3 million cash distribution from Nimbus Therapeutics, LLC (Nimbus) in connection with Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

• Schrödinger to Announce Fourth Quarter and Full-Year 2022 Financial Results on February 28

  2/13/2023

  Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2022 financial results on Tuesday, February 28, 2023, after the financial markets close.

• Schrödinger to Present at SVB Securities Global Biopharma Conference

  1/31/2023

  Schrödinger today announced that management will participate in the SVB Securities Global Biopharma Conference and will give a presentation on Tuesday, February 14, 2023, at 1:00 p.m. ET.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - January 20, 2023

  1/20/2023

  Schrödinger, Inc. today reported that on January 16, 2023, the company granted (i) non-statutory stock options to purchase an aggregate of 14,300 shares of the company’s common stock to six newly hired employees, including three newly hired employees based outside of the United States and (ii) restricted stock units (RSUs) with respect to 4,350 shares of the company’s common stock to one newly hired employee.

• Schrödinger Provides Update on Progress Across the Business and Outlines 2023 Company Strategic Priorities

  1/9/2023

  Schrödinge , Inc. today provided an update on its progress across the business and announced its strategic priorities for 2023.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 16, 2022

  12/16/2022

  Schrödinger, Inc. reported that on December 15, 2022, the company granted non-statutory stock options to purchase an aggregate of 26,350 shares of the company’s common stock to seven newly hired employees, including two newly hired employees based outside of the United States.

• Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting

  12/12/2022

  Schrödinger , Inc. today announced new preclinical data on its potent and selective CDC7 inhibitor, SGR-2921, in a poster session at the American Society of Hematology (ASH) 64th Annual Meeting taking place virtually and in New Orleans, Louisiana.

• Schrödinger to Present at Piper Sandler 34th Annual Healthcare Conference

  11/21/2022

  Schrödinger today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference.

• Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - November 18, 2022

  11/18/2022

  Schrödinger, Inc. reported that on November 15, 2022, the company granted non-statutory stock options to purchase an aggregate of 32,165 shares of the company’s common stock to eight newly hired employees, including two newly hired employees based outside of the United States.

• Schrödinger to Present at Jefferies 13th Annual London Healthcare Conference

  11/7/2022

  Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced that management will participate in a fireside chat at the Jefferies 13th Annual London Healthcare Conference in London, UK.